Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 1CNS 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 10Neuroendocrine Tumors 7Neoplasm Metastasis 7Recurrence 4Tuberous Sclerosis 3Triple Negative Breast Neoplasms 3Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3von Hippel-Lindau Disease 2Skin Neoplasms 2Sarcoma 2Meningioma 2Glioma 2Gastro-enteropancreatic neuroendocrine tumor 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Adenoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

belzutifan 4Everolimus 2spartalizumab 1palbociclib 1lenvatinib 1gallium Ga 68 dotatate 1cabozantinib 1Nivolumab 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
von Hippel-Lindau Disease × Everolimus × 1 year × Clear all
NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡